The effect of amniotic membrane extract on umbilical cord blood mesenchymal stem cell expansion: is there any need to save the amniotic membrane besides the umbilical cord blood?

Zahra Vojdani 1, Ali Babaei 1, Attiyeh Vasaghi 1, Mojtaba Habibagahi 2, Tahereh Talaei-Khozani 1 *

1 Laboratory for Stem Cell Research, Anatomy Department, Shiraz University of Medical Sciences, Shiraz, Iran
2 Immunology Department, Shiraz University of Medical Sciences, Shiraz, Iran

**ARTICLE INFO**

**Article type:** Original article

**Article history:**
Received: May 25, 2015
Accepted: Nov 5, 2015

**Keywords:** Amnion, Basic-fibroblast growth-factor, Wharton’s jelly, Mesenchymal stem cell

**ABSTRACT**

**Objective(s):** Umbilical cord blood is a good source of the mesenchymal stem cells that can be banked, expanded and used in regenerative medicine. The objective of this study was to test whether amniotic membrane extract, as a rich source of growth factors such as basic-fibroblast growth factor, can promote the proliferation potential of the umbilical cord mesenchymal stem cells.

**Materials and Methods:** The study design was interventional. Umbilical cord mesenchymal stem cells were isolated from voluntary healthy infants from hospitals in Shiraz, Iran, cultured in the presence of basic-fibroblast growth factor and amniotic membrane extracts (from pooled - samples), and compared with control cultures. Proliferation assay was performed and duplication number and time were calculated. The expression of stem cell’s specific markers and the differentiation capacity toward osteogenic and adipogenic lineages were evaluated.

**Results:** Amniotic membrane extract led to a significant increase in the proliferation rate and duplication number and a decrease in the duplication time without any change in the cell morphology. Both amniotic membrane extract and basic-fibroblast growth factor altered the expressing of CD44 and CD105 in cell population. Treating basic-fibroblast growth factor but not the amniotic membrane extract favored the differentiation potential of the stem cells toward osteogenic lineage.

**Conclusion:** The amniotic membrane extract administration accelerated cell proliferation and modified the CD marker characteristics which may be due to the induction of differentiation toward a specific lineage. Amniotic membrane extract may enhance the proliferation rate and duplication number of the stem cell through changing the duplication time.

**Introduction**

Friedenstein and colleagues reported the isolation of mesenchymal stem cells (MSC) from guinea pig bone marrow in 1970. They named the isolated cells as fibroblast-colony forming unit because the cells were adherent to the plate and showed a fibroblast-like morphology (1). The MSCs can proliferate in vitro and differentiate in an appropriate environment to mesodermal lineages such as osteoblast, chonroblast and adipocyte (2). Further research showed that mesenchymal stem cells can be differentiated into the non-mesodermal tissues such as hepatocyte (3), neuron (4), and insulin producing cells (5).

An alternative source of mesenchymal stem cells is umbilical cord blood. Umbilical cord blood is discarded as a medical waste after parturition. It is a good source for therapeutic purposes because they are non-immunogenic, can be prepared by a non-invasive procedure, and are free from ethical issues (6). The cord blood contains a rich source of stem cells including hematopoietic cells (7) as well as MSCs (8). The cells derived from the cord blood are more immature and, therefore, their differentiation potential is more than bone marrow-derived MSCs (BMMSC). Human umbilical cord blood mesenchymal stem cells (HUCBSC) have a longer telomere length (8) and express a lower level of CD106 compared to the BMMSCs. It has been shown that the mesenchymal stem cells derived from the umbilical cord have less chance to be contaminated with viral infectious agents (9). In
spite of all advantages, HUCBMSC has less capacity to form colony than BMMSC and Wharton’s jelly-derived MSC (10); therefore, supplying sufficient numbers of the cells is a critical hindrance for the clinical cell therapy approaches. To increase the proliferation capacity of the MSCs, it has been suggested that culture media should be supplemented with basic-fibroblast growth factor (bFGF) (10). In fact, bFGF is the most common growth factor added to MSC culture media to accelerate cell proliferation (11) and reduce the population doubling time (12). However, bFGF can modify the differentiation capacity of MSC in favor of the osteogenic lineage and limits its neurogenic capacity (11).

There is a controversy regarding the effects of bFGF on immunophenotype characteristic of the stem cells. Basic fibroblast growth factor has been reported to reduce the expression of some surface CD markers such as CD44 (13); meanwhile, others reported no modification in immunophenotype characteristic (12). CD44 is a transmembrane glycoprotein that has significant roles in cell growth, survival, differentiation (14), cell adhesion, motility, matrix degradation and proliferation (15). Down-regulation of CD105 in HUCBMSGs was reported after the beginning of the differentiation process (16). CD105 or endoglin is another transmembrane glycoprotein (17) and it has been shown that its overexpression leads to an enhancement in cell proliferation (18). Changes in the expression of the CD markers involved in cell division can alter cell proliferation rate.

Amniotic membrane (AM) is another waste product of delivery process. It composes of 3 layers: the epithelial layer, basement membrane and underlying connective tissue (19). Amniotic membrane can produce a verity of growth enhancing substances such as epidermal growth factor, transforming growth factor (TGF)-alpha, keratinocyte growth factor (KGF), hepatocyte growth factor (HGF), bFGF, TGF-beta1, -beta2, -beta3 (20), protease inhibitors (21) and heparin sulfate proteoglycan (22). The production of growth factors by AM promotes wound healing (21) and accelerates epithelialization (23).

Amniotic membrane extract (AME) was shown to cure the chemical corneal burn because of its anti-inflammatory effects (23). Moreover, it has been also reported that the growth factor content of the amnion led to endothelial cell proliferation (24). Soluble factors in the AM stroma have been demonstrated to modify the differentiation of the mesenchymal cell (25). AME was reported to increase the limbal cell viability (26) and contain essential substances for treatment of corneal defect (27).

The cell yield of the isolated blood samples was low and amniotic membrane extract as a rich source of growth factors such as bFGF (20) can potentially induce HUCBMSC proliferation. However, the administration of bFGF as a proliferative factor could change the immunophenotyping (13) and differentiation potential of the cells toward osteogenic lineage (11). Besides, b-FGF is an expensive growth factor that causes a higher cost for cell therapy and also changes the stem cell features. Therefore, this study was designed to find a reliable substitute for bFGF. To do this, we investigated the effects of human AME on the proliferation capacity of HUCBMSGs.

**Material and Methods**

**Umbilical cord blood mesenchymal stem cell isolation**

The experimental procedures were in accordance to the university ethical committee guidelines. Mesenchymal stem cells were isolated from the cord blood of 100 full-term healthy infants delivered by cesarean sections in Hafez hospital, Shiraz, Iran with informed parental consents. The blood samples were transferred into the falcon tubes containing 500 U of heparin (Rotemmedica, Germany). The mononuclear cells (MNC) were separated through density gradient centrifugation over ficoll (Biosera, UK). The MNC was removed and washed with DMEM (biosera, UK). The cells were re-suspended in DMEM containing 10% FCS, 1% penicillin/streptomycin and 1%L-Glutamin, plated in T25 flasks, and kept at 37 °C and 5% CO₂ for 3 days. The culture media were replaced every 3 days.

**Preparation of amniotic membrane extract**

The amniotic membrane was separated from the chorionic membrane and washed in cold phosphate buffer saline (PBS) containing 1% penicillin/streptomycin. A pool of ten amniotic membranes were minced into small pieces on ice and treated with trypsin for 10 min at 37 °C and 5% CO₂. The amniotic membrane pieces were centrifuged at 800 RPM for 5 min and the supernatant was discarded. The membranes were snap-frozen in liquid nitrogen. The membranes were thawed on ice in the presence of PBS containing protease inhibitor (Sigma, USA), and thereafter, homogenized at the amplitude 80-90% in a total time of 5 min and pulse 30/10. The cell lysate was then centrifuged at 3000 RPM at 4 °C for 10 min. The supernatant was centrifuged once more at 12 000 RPM at 4 °C for 20 min. The supernatant was aliquoted at 100 µl and snap-frozen in liquid nitrogen and transferred to -80 °C until use. The protein yield of the extract was assessed by Bradford protein assay. Cytotoxicity of the extract was assessed by culturing 50 000 cells in the presence of the serial dilutions of the extract. The cell survival was evaluated with Neutral Red assay.
Experimental design

The cells were divided into 3 parts and cultured in the following conditions: DMEM containing 10% FCS (as control culture), the same culture medium containing the AME at a concentration of 480 µg/ml (21) (as experimental culture) or bFGF (Sigma, USA) and heparin at a concentration of 5 ng/ml and 5 µg/ml, respectively (as a positive control culture).

Immunophenotyping

The cultured cells were harvested at the second passage and washed with PBS containing 2% FCS. Aliquots of 1 × 10^6 per 100 µl cells were separately stained with combinations of antibodies against CD44, CD90, CD144 (FITC conjugated), CD105 (PerCP conjugated), CD106 (PE-conjugated) and CD34 (PE-conjugated) (all from Abcam, UK, Cambridge). Isotype matched antibodies were used to exclude non-specific bindings. A four color FACS caliber flowcytometry machine with CellQuest pro software for acquisition of data was used to analyze the stained cells. The WinMDI-free software was used for graphical presentation of the results.

Osteogenic differentiation

Osteogenic differentiation of the HUCBMSCs was stimulated by culturing the cells at the passage 2 in the presence of NH-Osteo Diff Medium (MACS, Germany) with or without supplementation with bFGF or AM extract. The cells were cultured for 4 weeks and stained with Alizarin Red S.

Adipogenic differentiation

Adipogenic differentiation of the HUCBMSC was induced by culturing the cells at the passage 2 in the DMEM supplemented with human adipogenic stimulatory supplements (Stem Cell Technologies Inc, Canada). Amniotic membrane extract or bFGF was also added to the media to evaluate their impact on adipogenic differentiation as well. The cultured cells were harvested at the second passage of MSCs. The exposure of the UCBMSC to the AME or bFGF did not change the MSCs morphology. The cell yield of the blood samples was 30% and the protein yield of the extract was determined as 7.2 mg/ml by Bradford assay.

Proliferation assay

All the cultures were exposed to the 50 ng/ml of BrdU (Sigma, USA) for 12 hr before they were harvested. The harvested cells were washed with PBS, re-suspended at. 5× 10^5 - 1×10^6 cells/ml, fixed in 70% ethanol for 5 min at room temperature, and then washed again. Afterward, the fixed cells were incubated in 1.5 M HCl at 37 °C for 30 min, washed with PBS containing 0.5% BSA, and kept in the same buffer for 10 min at room temperature. Anti-BrdU rat monoclonal antibody (1:40) (Abcam, UK, Cambridge) was added to the cells and incubated for 1 hr at room temperature. Lastly, anti-rat FITC-conjugated secondary antibody (1:100) (Abcam, UK, Cambridge) was added and incubated for 30 min at room temperature. After washing with PBS, the cells were post-fixed in 1% parafomaldehyde. The percentages of the positive cells were analyzed by flowcytometry. All graphs were depicted by WinMDI software.

Statistical analyses

All the experiments were performed in at least triplicate. The data were analyzed by Analyze of Variances (ANOVA) and Least Standard Deviation (LSD). The analysis was done using SPSS 15.0 for windows (IBM, USA) and graphically presented by Microsoft Excel. A P value less than 0.05 was considered as statistically significant.

Results

Umbilical cord blood culture

In the primary cultures of HUCBMSCs, two types of the cells were observed; fibroblast-like cells with spindle or satellite shape and osteoclast-like cells with polygonal to flat-shape morphology where the osteoclast-like cells were tightly attached to the plate and could not be harvested easily. In this way, we were able to harvest and separate most of the fibroblast-like cells from osteoclast-like cells by different cell attachment property at the first passage of the cultures (Figure 1). In most cases, osteoclast-like cells could not be seen at the second passages of MSCs. The exposure of the UCBMSCs to the AME or bFGF did not change the MSCs morphology. The cell yield of the blood samples was 30% and the protein yield of the extract was determined as 7.2 mg/ml by Bradford assay.
Figure 1. Mesenchymal stem cells isolated from the cord blood contain two types of cells, fibroblast-like and osteoclast-like cells. The primary culture contains a large number of osteoclast-like cells (A) while they are rare in the first passage (B).

The cytotoxicity assay was performed to find the best extract dilution and the results revealed that the extract dilution at 1:15 was not toxic as compared with bFGF and control cultures.

**CD Marker expression**

The fibroblast-like cells in the control cultures (with base culture media without bFGF or AM extract) were negative for the expression of CD34, CD144 and CD90 (0.22% ± 0.32, 0.25% ± 0.26 and 0.08% ± 0.04; respectively). Most, but not all, fibroblast-like cells were CD105-CD106-. The frequencies of positive cells for CD105 and CD106 were 22.61 ± 5.6 and 7.3 ± 4.6, respectively. However, they expressed CD44 (73.4% ± 4.6). The administration of the AME or bFGF led to a significant decrease in the percentage of the cells with CD105 (4.1% ± 1.5 and 4.6% ± 1.9; respectively) and CD44 (25.8% ± 4.0 and 23.3% ± 7.6; respectively) expression (Figure 2). The percentages of different cell populations in the second passage are summarized in Table 1.

**The Proliferation rate of the cells**

The flowcytometry data showed that the percentages of the BrdU-positive cells significantly increased in the AME-treated cultures compared to the control cultures (71.48% ± 17.28 and 46.25% ± 17.18; respectively) (P=0.035) (Figure 3). On the other hand, although the percentage of the BrdU-positive cells in the cultures exposed to bFGF (67.88 ± 12.89) also increased, the statistical analyses showed no significant difference with control cultures (P= 0.091) (Figure 4).

**Cell number duplication and doubling time**

The data showed a significant reduction in the duplication time after the cells were exposed to the AME or bFGF compared to the control cultures (P=0.002 and 0.003, respectively). The duplication number also increased significantly in the extract- and bFGF-treated cells compared to the control (P=0.004) (Table 2).
**Table 1.** The percentages of umbilical cord blood mesenchymal stem cells expressed the CD marker in extract- or bFGF-treated cultures compared to the negative control

| CD markers | Negative control (mean ±SD) | Extract- treated (mean ±SD) | bFGF-treated (mean ±SD) | P value |
|------------|-----------------------------|-----------------------------|------------------------|---------|
| CD44       | 73.4±4.6                    | 25.8±4.0*                   | 23.3±7.6*              | 0.000   |
| CD105      | 22.6±5.6                    | 4.1±1.5*                    | 4.6±1.9*               | 0.000   |
| CD106      | 7.3±4.6                     | 14.6±6.0                    | 9.6±5.3                | 0.305   |
| CD90       | 0.08±0.04                   | 0.33±0.31                   | 0.1±0.015              | 0.342   |
| CD34       | 0.22±0.32                   | 0.76±1.1                    | 0.17±0.07              | 0.521   |
| CD44       | 0.25±0.26                   | 0.36±0.55                   | 0.23±0.20              | 0.568   |

* Significant difference with negative control (P<0.05)

**Differentiation potential of the HUCBMSC**

The HUCBMSCs differentiated into adipocyte and osteocyte as indicated by Oil Red O and Alizarin Red S stains, respectively. The administration of the bFGF could increase the osteogenic potential of the HUCBMSCs. However, the osteogenic differentiation potential of the cells did not change by exposure to the extract as compared with the control cultures (Figure 5). The adipogenic capacity was reduced by bFGF treatments compared with the controls (Figure 6). The administration of the extract to the culture medium did not modify the adipogenic capacity of the HUCBMSC compared with the control culture.

**Discussion**

Sufficient number of the cells is essential for a successful cell therapy strategy and, therefore, it is important to reduce the duplication time and enhance the generation number to have a high yield of cells per culture volume. Basic Fibroblast Growth Factor as a mitogen can reduce the generation time; researchers have added it to the cultures of HUCBMSCs (12) or adipocyte derived-MSC (11) to enhance the cell proliferation. Our data also showed bFGF was able to reduce the duplication time and accelerated the proliferation rate of the HUCBMSCs. Basic fibroblast growth factor supplementation at a concentration higher than 5 ng/ml has been reported to alter cell morphology of BMMSCs (11). However, in our study 5 ng/ml of bFGF did not change the HUCBMSCs’ appearance. We also tested the AME to find if it can support or enhance the growth of HUCBMSCs as bFGF does. In fact, we showed that AME could accelerate the proliferation rate of the cells without changing the cell morphology. It has been shown that the supplementation of the media with a combination of growth factors containing bFGF, transforming growth factor and platelet-derived growth factor reduces the generation time.

**Table 2.** The comparison of the duplication time and number in the extract- or bFGF-treated cultures with negative control (mean ± SD)

| Dupplication time [min] | Negative control | Extract-treated culture | bFGF-treated culture |
|-------------------------|------------------|------------------------|---------------------|
|                         | 1419±00±00       | 9057±0.059.4*          | 9470±41.5.1*        |
| Dupplication number     | 0.40±09±0.48     | 0.64±07±0.06*          | 0.60±86±0.26*       |

* Significant difference with negative control (P<0.05)
Expansion of cord blood MSCs by amniotic membrane extract

Vojdani et al

Figure 4. The percentage of BrdU positive cells in cultures treated with ordinary medium (control), amniotic membrane extract or bFGF.

Figure 5. Osteogenic capacity of umbilical cord blood mesenchymal stem cells: A, the cells cultured in ordinary medium; B, the cells cultured in the presence of osteogenic medium; C, osteogenic capacity of the cells in the presence of bFGF; and D, amniotic membrane extract. Alizarin red S staining.

Figure 6. Adipogenic capacity of the umbilical cord blood mesenchymal stem cells: A, the cells cultured in ordinary medium; B, the cells cultured in the presence of adipogenic medium; C, adipogenic capacity the cells cultured in the presence of bFGF; and D, amniotic membrane extract. Oil red O staining.

Increase in the ulcer fibroblast proliferation was shown by administration of AME (31). It has been also reported that the AME accelerate the cell proliferation and cell viability in the human limbal and corneal epithelium (26). The present study also revealed that AME supplementation could accelerate the cell proliferation rate even better than the proliferation rate in bFGF-treated cultures.

Similar to bFGF, AME could alter the expression of CD105 and CD44 markers in the growing HUCBMSCs. Literature showed controversial reports about the effect of bFGF on CD44 expression pattern. It has been reported that the proliferation of CD44+ cancer cell population is decreased by administration of bFGF in a dose dependent manner (13). Some researchers reported a decrease in the frequency of CD44 expressing cells after administration of bFGF to the culture medium of human BMMSCs (11, 32). However, the others demonstrated an increase in the CD44 positive cells after exposing the cells isolated from mouse periodontal ligament to bFGF (33). Our data confirmed the findings of Sotiropoulou et al (11) and Nakagawa et al (32) that isolated the cells from the same species as we did.

Adding bFGF to the culture media alters the differentiation potential of BMMSCs toward osteogenic and at a lower extent toward adipogenic lineages (10). Our data showed similar results as the differentiation potential toward osteogenic lineage of the HUCBMSCs increased by supplementation of the culture media with bFGF. However, we found a reduction in adipogenic differentiation potential of HUCBMSCs after administration of bFGF. On the other hand, the AME supplementation did not alter the differentiation capacity of the HUCBMSCs in comparison with the effect of bFGF. Therefore, changing the differentiation capacity of MSCs in the presence of bFGF may interfere with treatment in some cell therapy approaches.

Conclusion

AME could enhance the proliferation rate and duplication number of the HUCBMSC by reducing the generation time. The AME content may exert their effects by promoting the reduction of expression of some surface markers like CD44. Besides, AME led to an increase in proliferation rate without altering cell morphology or differentiation capacity toward osteogenic or adipogenic lineage. Therefore, the AME can be used to increase cell proliferation rate and to prepare a sufficient number of the HUCBMSCs for cell therapy approaches.

Acknowledgment

The authors wish to thank research deputy of Shiraz University of Medical Sciences for offering the
grant no 5592 and also M Salmannejad for technical supports and Shiraz University of Medical Sciences. Shiraz, Iran and also Center for Development of Clinical Research of Nemazee Hospital and Dr Nasrin Shokrpour for editorial assistance. The results described in this paper were part of a thesis written by Babaei.

References
1. Friedenstein AJ, Chailakhjan RK, Lalykina KS. The development of fibroblast colonies in monolayer cultures of guinea-pig bone marrow and spleen cells. Cell Tissue Kinet 1970; 3:393-403.
2. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999; 284:143-147.
3. Borhani-Haghighi M, Talaei-Khazani T, Ayatollahi M, Vojdaniz Z. Wharton’s jelly-derived mesenchymal stem cells can differentiate into hepatocyte-like cells by hepg2 cell line extract. Iran J Med Sci 2015; 40:143-151.
4. Ma K, Fox L, Shi G, Shen J, Liu Q, Pappas JD, et al. Generation of neural stem cell-like cells from bone marrow-derived human mesenchymal stem cells. Neurul Res 2011; 33:1085-1093.
5. Gabr MM, Zakaria MM, Refae AF, Ismail AM, Abou-El-Mahasen MA, Ashamalah SA, et al. Insulin-producing cells from adult human bone marrow mesenchymal stem cells control streptozotocin-induced diabetes in nude mice . Cell Transplant 2013; 22:133-145.
6. Taghizadeh RR, Cetrulo KJ, Cetrulo CL. Wharton’s Jelly stem cells: Future clinical applications. Placenta 2011; 32:S311-S315.
7. Broxmeyer HE, Douglas GW, Hangoc G, Cooper S, Bard J, English D, et al. Human umbilical cord blood as a potential source of transplantable hematopoietic stem/progenitor cells. Proc Natl Acad Sci U S A 1989; 86:3828-3832.
8. Köglr G, Sensken S, Airey JA, Trapp T, Münser M, Feldhahn N, et al. New human somatic stem cell from placental cord blood with intrinsic pluripotent differentiation potential. J Exp Med 2004; 200:123-135.
9. Malgieri A, Kantzari E, Patrizi MP, Gambardella S. Bone marrow and umbilical cord blood human mesenchymal stem cells: state of the art. Int J Clin Exp Med 2010; 3:248-269.
10. Nguyen TH, Paluck SJ, McGahan AJ, Maynard HD. Poly (vinyl sulfonate) Facilitates bFGF-Induced Cell Proliferation. Biomacromolecules 2015; 16:2684-2692.
11. Sotiropoulou PA, Perez SA, Salagianni M, Baxevanis CN, Papamichail M. Characterization of the optimal culture conditions for clinical scale production of human mesenchymal stem cells. Stem Cells 2006; 24:462-471.
12. Ramasamy R, Tong CK, Yip WK, Vellasamy S, Tan BC, Seow HF. Basic fibroblast growth factor modulates cell cycle of human umbilical cord-derived mesenchymal stem cells. Cell Prolif 2012; 45:132-139.
13. Yang ZL, Cheng K, Han ZD. Effect of bFGF on the MCF-7 Cell Cycle with CD44(+)/CD24(-): Promoting the G0/G1→G2/S Transition. J Breast Cancer 2012; 15:388-392.
14. Ponta H, Sherman L, Herrlich PA. CD44: from adhesion molecules to signaling regulators. Nat Rev Mol Cell Biol 2003; 4:33-45.
15. Marhava R, Zöller M. CD44 in cancer progression: adhesion, migration and growth regulation. J Mol Histol 2004; 35:211-231.
16. Jin HJ, Park SK, Oh W, Yang YS, Kim SW, Choi SJ. Down-regulation of CD105 is associated with multilineage differentiation in human umbilical cord blood-derived mesenchymal stem cells. Biochem Biophys Res Commun 2009; 381:676-681.
17. Gougos A, St Jacques S, Greaves A, O’Connell PJ, d'Apice AJF, Buhring H-J, et al. Identification of distinct epitopes of endoglin, an RGD-containing glycoprotein of endothelial cells, leukemic cells, and syncytiotrophoblasts. Int Immunol 1992; 4:83-92.
18. Fonsatti E, Del Vecchio L, Akomente M, Siglotti L, Nicotra MR, Coral S, et al. Endoglin: an accessory component of the TGFB-beta-binding receptor-complex with diagnostic, prognostic, and bioimmunotherapeutic potential in human malignancies. J Cell Physiol 2001; 188: 1-7.
19. Sippel KC, Ma JJ, Foster CS. Amniotic membrane surgery. Curr Opin Ophthalmol 2001; 12:69-81.
20. Koizumi NJ, Inatomi TJ, Sotozono CJ, Fullwood NJ, Quantock AJ, Kinoshita S. Growth factor mRNA and protein in preserved human amniotic membrane. Curr Eye Res 2000; 20:1:73-177.
21. Kim JS, Kim JC, Na BK, Jeong JM, Song CY. Amniotic membrane patching promotes healing and inhibits proteinase activity on wound healing following acute corneal alkali burn. Exp Eye Res 2000; 70:329-337.
22. Niknejad H, Yazdanpanah G, Kakavand M. Extract of fetal membrane would inhibit thrombosis and hemolysis. Med Hypotheses 2015; 85:197-202.
23. Liang L, Li W, Ling S, Sheha H, Qiu W, Li C, et al. Amniotic membrane extraction solution for ocular chemical burns. Clin Exp Ophthalmol 2009; 37:855-863.
24. Kooob TJ, Lim JJ, Massae M, Zabok N, Renert R, Gurtner G, et al Angiogenic properties of dehydrated human amnion/chorion allografts: therapeutic potential for soft tissue repair and regeneration. Vasc Cell 2014; 1:6:10.
25. Li W, He H, Chen YT, Hayashida Y, Tseng SC. Reversal of myofibroblasts by amniotic membrane stromal extract. J Cell Physiol 2008; 215:657-664.
26. Dudok DV, Nagdee I, Cheung K, Liu H, Vedovelli L, Ginelli E, et al. Effects of amniotic membrane extract on primary human corneal epithelial and limbal cells. Clin Exp Ophthalmol 2015; 43:443-448.
27. Kordić R, Sertić SP, Jandrolović S, Kalauz M, Kuzman T, Skegro I, et al. Application of the amniotic membrane extract (AMX) for the persistent epithelial defect (PED) of the cornea. Coll Antropol 2013; 37:161-164.
28. Korzynska A, Żychowicz MA. Method of estimation of the cell doubling time on basis of the
cell culture monitoring data. Biocybern Biomed Eng 2008; 28:75–82.
29. Li IC, Wu SC, Fu J, Chu EH. A deterministic approach for the estimation of mutation rates in cultured mammalian cells. Mutat Res 1985; 149:127-132.
30. Barbero A, Palumberi V, Wagner B, Sader R, Grote MJ, Martin I. Experimental and mathematical study of the influence of growth factors on the growth kinetics of adult human articular chondrocytes. J Cell Physiol 2005; 204:830-838.
31. Tauzin H, Robin S, Humbert P, Viennet C, Saas P, Courderot-Masuyer C, et al. Can leg ulcer fibroblasts phenotype be influenced by human amniotic membrane extract? Cell Tissue Bank 2014; 15:251-255.
32. Nakagawa H, Akita S, Fukuim M, Fuji T, Akino K. Human mesenchymal stem cells successfully improve skin-substitute wound healing. Br J Dermatol 2005; 153:29-36.
33. Shimabukuro Y, Terashima H, Takedachi M, Maeda K, Nakamura T, Sawada K, et al. Fibroblast growth factor-2 stimulates directed migration of periodontal ligament cells via PI3K/AKT signaling and CD44/hyaluronan interaction. J Cell Physiol 2011; 226:809-821.